Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Darzalex Faspro (daratumumab/hyaluronidase)
i
Other names:
Dara SC, daratumumab/rHuPH20, DARA + rHuPH20 , daratumumab SC
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Trials
Company:
Genmab, Halozyme, J&J
Drug class:
CD38 inhibitor
Related drugs:
‹
daratumumab (26)
isatuximab-irfc (11)
SAR442257 (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
MOR202 (1)
TAK-079 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
GEN3014 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
NY-338 (0)
SG2501 (0)
SG301 IV (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
SAR650984 SC (0)
TAK-573 (0)
daratumumab (26)
isatuximab-irfc (11)
SAR442257 (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
MOR202 (1)
TAK-079 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
GEN3014 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
NY-338 (0)
SG2501 (0)
SG301 IV (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
SAR650984 SC (0)
TAK-573 (0)
›
Associations
(4)
News
Trials
Search handles
@mtmdphd
Search handles
@mtmdphd
Filter by
Latest
9ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
9 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
9ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
9 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
10ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
10 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
10ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
10 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
10ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
10 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
10ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOeiugZ #NCT04071457 #mmsm (@mtmdphd)
10 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
11ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
11 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
11ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
11 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
11ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
11 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
11ms
Kashyap Padmaraju presents cool data on achieving better quality of care for #MultipleMyeloma patients with subcutaneous #Daratumumab treatment without any premedication. @bdermanmd @UChicagoHemOnc @UCCancerCenter @UChicagoMed (@UCCancerCenter)
11 months ago
Clinical
|
Darzalex Faspro (daratumumab/hyaluronidase)
11ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
11 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
11ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
11 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
11ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
11 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
11ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
11 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
11ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
11 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
11ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
11 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
11ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
11 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
11ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
11 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
over5years
VIDEO: Ajai Chari @IcahnMountSinai on #subcutaneous #daratumumab: combining safety, efficacy & convenience: https://t.co/drq9RJ6GzB #ASCO18 @ASCO #Myeloma #MultipleMyeloma #MMSM #ClinicalTrials #CTSM #hcsm #Toxicity #Infusion #HemOnc #HemeOnc #Antibodies #CaxTx (@VJHemOnc)
over 5 years ago
Clinical • Video
|
Darzalex Faspro (daratumumab/hyaluronidase)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login